Inhibiting SUMOylation for inflammatory bowel disease

Inhibiting the post-translational modification SUMOylation could help treat inflammatory bowel disease by increasing expression of the anti-inflammatory cytokine IL-10 in the colon while decreasing proinflammatory cytokine expression, thus reducing intestinal injury.

Levels of the SUMOylation enzymes SUMO2 and SUMO3 were higher in colon samples from Crohn’s disease patients and mice exposed to the ulcerative colitis-inducing compound dextran sulfate sodium (DSS) than in samples from individuals without inflammatory bowel disease and healthy control mice, respectively. ...